Please login to the form below

Not currently logged in
Email:
Password:

haemophilia B

This page shows the latest haemophilia B news and features for those working in and with pharma, biotech and healthcare.

UniQure skyrockets on haemophilia B gene therapy data

UniQure skyrockets on haemophilia B gene therapy data

The phase 2b results for UniQure’s AMT-061 candidate for haemophilia B keeps the Dutch-US biotech in contention with Pfizer and Spark, its main competitor in the development of ... Both are delivering the gene for the missing clotting factor in

Latest news

More from news
Approximately 3 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... Portfolio/pipeline in haemophilia and other rare

  • Deal Watch August 2016 Deal Watch August 2016

    premiums. One commentator suggested BioMarin could be a Plan B for Sanofi. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

  • A rare opportunity A rare opportunity

    Sobi, handing Sobi commercialisation control over the haemophilia A treatment just four months after it received EU approval. ... Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for

  • Deal Watch February 2016 Deal Watch February 2016

    of haemophilia A and B.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Exercise of opt-out/ termination. 945. Macrogenics / J&J. MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical). ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics